Theravance Biopharma, Inc.
TBPH
$16.48
-$0.04-0.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -4.93M | 61.02M | 3.62M | 54.84M | -13.58M |
| Total Depreciation and Amortization | 1.44M | 1.51M | 1.41M | 1.35M | 1.38M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 945.00K | 3.79M | 5.35M | -5.91M | 3.30M |
| Change in Net Operating Assets | 75.83M | -72.38M | -16.88M | 157.80M | 51.94M |
| Cash from Operations | 73.28M | -6.06M | -6.51M | 208.07M | 43.04M |
| Capital Expenditure | -- | -8.00K | 0.00 | -34.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 52.59M | 596.00K | -100.25M | -36.22M | 30.63M |
| Cash from Investing | 52.59M | 588.00K | -100.25M | -36.26M | 30.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 241.00K | 488.00K | 278.00K | 0.00 | 20.00K |
| Repurchase of Common Stock | -5.82M | -1.98M | -678.00K | -503.00K | -874.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -5.58M | -1.49M | -400.00K | -503.00K | -854.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.30M | -6.97M | -107.15M | 171.31M | 72.82M |